Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report

Mediators of Inflammation

Volumn 8, Issue 1, 1999, Pages 13-15

  Sermet Gaudelus, I ^a   Stoven, V ^b   Annereau, J P ^b   Witko Sarsat, V ^a   Reinert, P ^c   Guyot, M ^d   Descamps Latscha, B ^a   Lallemand, J Y ^b   Lenoir, G ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b ECOLE POLYTECHNIQUE   (France)

^c CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^d Hôpital Intercommunal ^*

Author keywords

ABC protein; Colchicine; Cystic fibrosis; Cystic fibrosis transmembrane regulator; Inflammation

Indexed keywords

COLCHICINE; CORTICOSTEROID; IBUPROFEN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATORY DISEASE; MALE; PRIORITY JOURNAL; RESPIRATORY FUNCTION; TREATMENT OUTCOME;

EID: 0032915250     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359990667     Document Type: Article

References (22)

1. 1. Koch C, Hoiby N. Pathogenesis of cystic fibrosis. Lancet 1993; 341: 1065-1069.
2. 2. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1082.
3. 3. Descamps-Latscha B, Döring G, Galanaud P, Lenoir G, Navarro J, Schaffar L. Inflammation in Cystic Fibrosis. Med Inflamm 1996; 5: 121-143.
4. 4. Auerbach HS, Williams M, Kirkpatrick JA, Cotten HR. Alternate day prednisolone reduces the morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; ii: 686-688.
5. 5. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 331: 848-854.
6. 6. Levy M, Spino M, Read E. Colchicine: a state of the art review. Pharmacother 1991; 11(3): 196-211.
7. 7. Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1987; 262: 17432-17436.
8. 8. Higgins CE ABC transporters: from microorganisms to man. Annu Rev Biol 1992; 8: 67-113.
9. 9. Tommasini R, Evers R, Vogt E, et al. The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. Proc Natl Acad Sci USA 1996; 93: 6743-6748.
10. 10. Lallemand JY, Stoven V, Annereau JP, Boucher J, Blanquet S, Barthe J, Lenoir G. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997; 350: 711-712.
11. 11. Stern RC. The diagnosis of cystic fibrosis. N Engl J Med 1997; 336: 487-491.
12. 12. Douglas WW, Ryu JH, Swensen SJ, et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. Am J Resp Crit Care Med 1998; 158: 220-225.
13. 13. Kelly SJ, Uri AJ, Freeland HS, et al. Effects of colchicine on IgE-mediated early and late airway reactions. Chest 1995; 107: 985-991.
14. 14. Dallaverde E, Fan PT, Chang YH. Mechanism of action of colchicine. V. Neutrophil adherence and phagocytosis in patients with acute gout treated with colchicine. J Pharmacol Exp Ther 1982; 223: 197-202.
15. 15. Peters-Golden M, McNish RW, Davis JA, et al. Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. Am J Physiol 1996; 271: 6 Pt 1, L1004-1013.
16. 16. Entzian P, Schlaak M, Seitzer U, et al. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung 1997; 175: 41-51.
17. 17. Vollrath V, Wielandt AM, Acuna C, et al. Effect of colchicine and heat shock on multidrug resistance gene and P-glycoprotein expression in rat liver. J Hepatol 1994; 21: 754-763.
18. 18. Eliseenkova AV, Kakpakova ES, Abdrjashitov RI, Stavrovskaya AA. Colchicine-resistance and enhancment of P-glycoprotein activity after co-cultivation of drug-sensitive cells with multidrug resistant variants. Cell Biol Int 1995; 19(2): 113-119.
19. 19. Wei LY, Stutts MJ, Hoffman MM, Roepe PD. Overexpression of the CFTR in NIH 3T3 cells lowers membrane potential and intracellular pH and confers a multidrug resistance phenotype. Biophys J 1995; 69: 883-895.
20. 20. Lindsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Cell Physiol 1998; 275(44): C323-326.
21. 21. Lindsdell P, Hanrahan JW. Adenosine triphosphate dependant assymetry of anion permeation in cystic fibrosis transmembrane conductance regulator chloride channel. J Gen Physiol 1998; 111: 601-614.
22. 22. Altschuler EL. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet 1998; 351: 1286.